8-K/A: Avanos Medical Appoints Interim CFO, Announces Executive Departure and Compensation Changes

Avanos Medical announces the departure of Michael Greiner, the appointment of Jason Pickett as Interim CFO and Treasurer, and related compensation adjustments.

Summary

• Avanos Medical announced that Michael C. Greiner will leave the company after serving as Interim CEO and previously as Senior Vice President and Chief Financial Officer.
• Greiner's departure is considered a qualifying termination under the company's Severance Pay Plan.
• He will receive a severance payment of $2,100,000, a prorated bonus for 2025, six months of COBRA premiums, and $50,000 in consulting fees for a one-month engagement.
• All of Greiner's special equity awards will vest immediately, while other unvested equity awards will terminate.
• Jason M. Pickett has been appointed as Interim Chief Financial Officer and Treasurer, effective April 14, 2025.
• Pickett will receive an annual salary of $350,000 and a monthly stipend of $30,000.
• He was also granted a special equity award of time-based restricted stock units with a grant date value of $200,000, vesting over 12 months.
• Warren J. Machan's consulting agreement was amended, ending his role as Interim CFO and transitioning him to a consultant until April 30, 2025, at a rate of $60,000 per month.

Sentiment

Score: 6

Explanation: The announcement includes both positive (appointment of a new Interim CFO) and negative (executive departure and associated costs) elements, resulting in a neutral sentiment.

Positives

• The company has quickly appointed a new Interim CFO and Treasurer in Jason Pickett.
• Michael Greiner's transition is being managed with a consulting period to ensure a smooth handover.

Negatives

• The departure of Michael Greiner, a former Interim CEO and CFO, may create uncertainty.
• The company is incurring significant severance costs related to Greiner's departure, totaling $2,100,000 plus other benefits.

Risks

• The transition period with multiple interim roles could create operational challenges.
• The company's performance against the relevant performance goals will determine the prorated bonus paid to Michael Greiner in 2026.

Future Outlook

The company will issue a new offer letter to Jason Pickett if the Interim Chief Financial Officer role is made official after the confidential search.

Management Comments

• John W. Cato, Vice President, Global Human Resources, stated that the amendment to Jason Pickett's offer letter captures the totality of the changes discussed with him.

Industry Context

Executive transitions and compensation adjustments are common in the medical device industry, reflecting the competitive market for talent and the need to incentivize key personnel.

Comparison to Industry Standards

• Severance packages for departing executives in similar-sized medical device companies often include a combination of cash severance, continuation of benefits, and accelerated vesting of equity awards.
• Interim executive compensation packages typically include a base salary, short-term incentives, and equity awards to align the executive's interests with the company's performance during the interim period.
• Companies like Medtronic and Stryker also use similar compensation structures for their executives.

Management Changes

Stakeholder Impact

• Shareholders may react to the executive changes and associated costs.
• Employees may experience uncertainty due to the leadership transitions.
• The changes could impact the company's financial performance and strategic direction.

Next Steps

• Preparation and execution of a Separation and Consulting Agreement between Avanos Medical and Michael Greiner.
• Jason Pickett will receive a new offer letter if appointed to the permanent CFO role.
• The company will determine and pay Michael Greiner's prorated bonus for 2025 in 2026.

Key Dates

Keywords

Interim CFO, Severance, Compensation, Executive Departure, Avanos Medical, Appointment